tool for research, a drawback to the use of ABPM is its expense. Clinic measurements tend to take no more than 10 min, require little preparation by patient or physician, and require inexpensive equipment. We estimate that ABPM has roughly a fivefold increase in cost compared to CBP (see Table 1 ). These extra costs are found in (i) the time it takes to use the device, including (a) recruiting and instructing patients (e.g., cannot shower or participate in strenuous exercise), (b) instrumenting and validating the device, (c) collecting equipment from participants and downloading data, once the monitoring period has ended, and (d) cleaning and inspecting the device; (ii) the increased cost of the device itself; and (iii) the increased reimbursement needed for research patients.
An undesirable choice. The apparent value of CBP is that it requires far less training, preparation, and expense than ABPM, and one can thus afford to collect data on a larger sample. However, the study results suffer due to the poor construct validity. Thus, researchers must choose between making use of CBP measures knowing their limitations, or bearing the greater expense of ABPM, to obtain desirable levels of statistical power. We offer a third alternative that yields equivalent power, but at decreased expense, to ABPM.
The two-method measurement approach
Two-method measurement (TMM) is a planned missingness design built around the strategy of combining data from a less expensive measure-one with questionable construct validityand data from a more costly measure (with superior construct validity). 5 At the heart of the TMM approach is the statistical model (Figure 1 ) that we call a bias control model. This model, which is estimated using structural equation modeling methods, partitions the variance of the less expensive measure between a latent variable measuring the construct of interest (BP in this instance), and a latent variable tapping the measurement bias associated with the less costly measures. As shown in Figure 1 , the less expensive measures "load" on both of these latent variables, or factors. A key assumption of the bias control model is that the more expensive measures, by virtue of their superior construct validity, load only on the substantive (BP) factor. This latent variable, and not CBP or ABPM individually, are used to predict an outcome variable. As shown in the figure, both BP and bias factors are then allowed to be related to the substantive outcome of interest. For the present analysis, we model BP (as measured by CBP and ABPM) to predict left ventricular mass (LVM), which is an indicator of heart damage, specifically left ventricular hypertrophy. 6 We use LVM as an example, but other clinical outcomes may of course be used.
The present research
In this paper, we illustrate the usefulness of the TMM approach using empirical data from a study in which CBP, ABPM, and LVM measures were taken. We used the observed empirical correlations between individual measures from this study to examine hypothetical designs that are compared to a design in which CBP and ABPM measures are both taken for 300 study participants. We illustrate two outcomes of the TMM analysis, depending on the researcher's goals: (i) the benefit in statistical power, holding constant the cost of collecting CBP and ABPM data for 300 study participants; and (ii) the cost benefit due to use of the TMM design in which statistical power is held constant. ABPM, ambulatory blood pressure monitoring; BP, blood pressure. a Unlike clinic measurements, when using ABPM a return appointment must be scheduled, or arrangements made for the patient to return the monitor (which may cost $3,000) by mail. Some patients must be called more than once and other efforts sometimes exerted to facilitate return. We add an estimated 10 min averaged across patients. b We deliberately minimized the costs associated with ABPM; many researchers and clinicians would have assigned greater amounts of time and greater costs, which would only increase the rationale for using the two-method measurement design. 
MeThods
We examined a data set that had been developed for other purposes, and from which other papers have been published. The methods used and rationale for the study are given elsewhere. 7 A brief synopsis of the methods is given here.
Participants. Data were available on 331 subjects (176 women, 155 men; aged 18-80; mean = 53.9), off of any hypertensive medications, with no previous cardiovascular events.
Measures, materials, and procedure. The data set contained the following variables that were germane to the present analysis:
(1) Ambulatory BP, collected using a SpaceLabs 90207 monitor (SpaceLabs, Redmond, WA), which has been shown to be valid. 8 Measure ments were taken every 15 min during the day and once per hour at night for 36 h (sleep time predetermined to begin at 10:00 pm and end at 6:00 am). These measures were repeated three times, 1 month apart. For each 36-h session, average systolic and diastolic BPs were collected for waking and sleeping hours. For the present study, we used an average of the total (waking + sleeping) systolic and diastolic BPs for each of the three 36-h periods, yielding three measures, labeled ABPM 1, ABPM 2, and ABPM 3. We also analyzed the data examining systolic and diastolic BP in separate models. We found a similar pattern of results, and thus they are not reported here. (2) CBP was taken three times before each of the three 36-h ambulatory monitorings by a highly trained physician using a mercury column sphygmomanometer. The six BP measures (three systolic, three diastolic, one each for each 36-h ambulatory monitoring period) were averaged, yielding three measures, labeled CBP 1, CBP 2, and CBP 3. As with ambulatory BP, we found a similar pattern of results when analyzing the data using separate models for systolic and diastolic BP (not reported here). (3) LVM was measured 10 weeks after BP data were collected via m-mode and two-dimensional echocardiograms.
Statistical procedures. The theoretical and technical aspects of the TMM design and its statistical justification as a planned missing data design have been published elsewhere. 5 The current manuscript is intended to provide an applied framework that can be used to guide the use of the method for a specific purpose, in this instance, the use of CBP and ABP. A brief overview of the TMM procedures follows. First, we estimated the bias-correction model in the empirical data set. This model can be estimated using any structural equation modeling program with a full information maximum likelihood-based feature for handling missing data. It is useful to examine the bias of the correction model in empirical data. It is also useful to compare the key factor correlation (BP with LVM) for the bias-correction model with the same correlation when BP is defined by the CBP measures only, and when BP is defined by the ABPM measures only. Note that when the TMM design has been implemented, this first step is sufficient. However, because our purpose here is to illustrate the benefits of the TMM approach in empirical studies like this one, we took the following steps as well to explain the TMM process.
Second, the next steps require that we have a correlation matrix for the seven measures (CBP 1, CBP 2, CBP 3, ABPM 1, ABPM 2, ABPM 3, LVM). Because we must take missing data into account, we generated the correlation matrix (data not shown) using the expectation maximization algorithm. 9, 10 Third, using a non-Monte-Carlo simulation procedure (described in detail elsewhere), 5 we examined several hypothetical variations of the TMM design. For illustration purposes, we started with a "complete cases" design in which CBP and ABPM data were collected from all N = 300 subjects. Because the costs associated with ABPM are five times those for CBP, we can choose not to collect ABPM data for some subjects, and this allows us to collect additional data (CBP only) on many new subjects. We first explored several variations of the TMM design in which the study costs remained the same as costs for the complete cases design. Finally, we explored several variations of the TMM design for which the statistical power remained the same as the power observed for the N = 300 complete cases design.
resulTs

Bias-correction model with empirical data
The bias-correction model depicted in Figure 1 was estimated using LISREL 8.54. 11 Overall, the model fit the data well. The six BP measures had strong and significant loadings on the BP factor. The three CBP measures also had smaller, but significant loadings on the bias factor. Most important, the BP and bias factors were each significantly related to LVM, r BP,LVM = 0.43, r bias,LVM = −0.26. For comparison, we also tested a model in which the BP factor was defined by CBP measures only, and one in which the BP factor was defined by ABPM measures only. For the CBP-only model, r BP,LVM = 0.29; for the ABPMonly model, r BP,LVM = 0.43 (the difference between r = 0.43 and r = 0.29 was statistically significant, X 2 (1) = 6.98, P < 0.01).
costs constant simulation
The complete cases design had N = 300 with both CBP and ABPM measures. The key results for this design are shown in the top row of Table 2 . The second row of Table 2 shows the results for a design in which we do not need to collect ABP data for 20 of the 300 subjects. Because of the 5 to 1 cost differential between ABPM and CBP measures, the cost savings from those 20 subjects allowed us to collect CBP data for 100 new subjects, bringing the total to N = 400; 280 of these have data for both CBP and ABPM measures; 120 have data for the CBP only. Each subsequent row of Table 2 shows a design in which another 20 ABPM measures were dropped, and another 100 new cases were added with CBP only. Note that all of the designs shown in Table 2 have the same cost ($41,400) as the complete cases design. Table 2 is the standard error for the unstandardized factor covariance for the BP factor association with LVM. The standard error for the complete cases model (top row) was 0.055. The standard error for the design shown in the second row was actually smaller: s.e. = 0.049. In fact, as the complete cases sample size decreased, and the sample size using CBP only increased, the standard error became smaller and smaller. The standard error was smallest for the design in the eighth row of Table 2 , the design with N = 170 complete cases, and N = 780 with CBP only. The statistical power associated with this design was equivalent to a complete cases design with N = 575. Thus, we would say that this design has an "effective" sample size of 575. 5 
AMERICAN JOURNAL OF HYPERTENSION | VOluME 25 NuMBER 7 | july 2012
original contributions
Two-Method Blood Pressure Model
Also shown in
statistical power constant simulation
In this simulation, we also started with the complete cases design with N = 300. We then explored alternative designs, varying the numbers of ABPM and CBP measures, but keeping constant the standard error for the covariance between the BP factor and LVM. The results related to this simulation appear in Table 3 . As shown in the top row of the table, the standard error for the key unstandardized factor covariance was 0.0549. In the second row of Table 3 , we show the design for which we dropped the number of complete cases arbitrarily by 50. We then asked: how many subjects with CBP only must we study using this design so that the key standard error remains at 0.0549? We found the required number was 62. That is, in addition to the 50 cases for which we collected CBP data only, we must add 12 new cases (with CBP only) to retain s.e. = 0.0549 for the key factor covariance estimate. Table 3 also shows three other design alternatives. For the design in the bottom row of the table, we had 100 complete cases. With this design, we needed 351 cases with CBP only in order to retain s.e. = 0.0549 for the key factor covariance estimate.
Note in Table 3 , however, that each design shown costs less than the design above it. In fact, the design shown in the bottom row of the table cost just more than half the cost of the complete cases design (top row). The standard error shown corresponds to the unstandardized factor covariance between the BP factor and LVM. The standardized estimate, i.e., the factor correlation, rounded to r = 0.43 for both designs shown. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CBP, clinic blood pressure; LVM, left ventricular mass. Our results showed that the standardized correlation between the BP factor and LVM was r = 0.43 for the bias-correction model. This correlation compared favorably with the correlation (also r = 0.43) observed when BP was defined using the ABPM measures only. These correlations were clearly superior (statistically and in a practical sense) to those obtained when BP was defined using the CBP measures only (r = 0.29). Furthermore, the magnitude of this relationship is similar to other research demonstrating that ABPM correlates with LVM in values ranging from 0.36 to 0.45. [12] [13] [14] These findings are important for the TMM design, because with this design, which is a planned missing data design, individuals are randomly selected to receive either both CBP and ABPM or just the CBP. This means that, as we showed in this work, the missing data procedures one uses to estimate the bias-correction model will have virtually the same estimates one would have if all subjects completed all measures. In both simulations, the standardized factor correlations between BP and LVM were virtually identical in the N = 300 complete cases models and in all TMM models (r = 0.43). More importantly, using a combination of less expensive (CBP) and more expensive (ABPM) measures led to substantial improvement in statistical power (effective N = 575 vs. 300), as shown in Table 2 , or a substantial cost savings for the study, as shown in Table 3 . The results suggest the usefulness of the TMM design for two purposes: (i) to increase statistical power, while maintaining construct validity and keeping study costs constant, or (ii) to hold statistical power constant and reduce study costs.
The "TMM design" represents an advance in methods for maximizing the efficiency of a particular measure while reducing the costs of collecting gold-standard data. The present study provides insight into a specific measurement problem, ABP vs. CBP. However, the technique is applicable to any such issues that fulfill the criteria: they are related to one another, one is more expensive than the other, and the more expensive measure is considered the gold standard compared to the less expensive measure. Thus, for example, one may have to decide between intravenous blood measures (preferred) to spot measures to detect levels or increases in various neurohormones; or a structured interview compared to a paper-and-pencil measure to assess depression; or heart rate variability measures using electrocardiogram (preferred) compared to a watch that is programmed to detect heart rate. The TMM method is a promising technique that in some studies may be able to decrease costs and/or increase one's power to detect effects.
limitations and future directions
For the assumptions of the method to hold, missing data must be planned (i.e., random assignment to ABPM+CBP or CBPonly conditions). That is, all individuals who failed to provide usable ABPM data, for example, cannot simply be grouped into a CBP-only condition, but rather the decision as to who will only have CBP data must be determined before data collection. Put another way, the missingness must be completely at random. 9 However, designs are also feasible in which the probability of receiving the more expensive measure (ABPM) is dependent on the subject's score on the less expensive measure (CBP). 5 In addition, although it is conceivable that Bayesian procedures might be developed to allow estimation of the bias control model with usual multiple regression techniques, at present, the models described here must be estimated using structural equation modeling techniques. Furthermore, the TMM approach performs best when a gold-standard measure exists. Although the TMM approach will often work well when one can simply act as though the expensive measure were a gold standard, one key element is that the scores on the expensive measure should not be under the subject's control. Also, the benefits of the TMM design are related to the cost differential between the expensive and cheap measures. We have shown here that a 5:1 cost ratio can work very well. Finally, although it may be possible in the future to adapt latent class methods to allow judgments about individual subjects, at present the TMM approach described here is best suited for research purposes and not clinical settings where judgments about individuals is paramount.
A second potential limitation concerns the cost difference to conduct the entire study, with more subjects, compared to the cost, and cost savings, for the BP measure alone. If the cost of running additional subjects is minimal, then the TMM approach is useful and recommended. If, however, the fixed costs per subject are sufficiently high (e.g., costs for assays or subject payment), they complicate assessment of the savings due to the reduced number of ambulatory monitorings that are required. Cost savings as we have described them here may be reduced in these "broad-focus" studies, and it may no longer be useful to employ a TMM design. 15 In other words, the researcher must balance the reduced cost associated with fewer ABPMs with the increased costs of running more participants. With that said, there are also hidden, or indirect benefits of the TMM approach, even in broad-focus studies, that must be taken into account when evaluating the overall benefits of the TMM approach. For example, because more participants will have completed the study, there will be greater power to detect effects for secondary analyses, such as examining how a personality characteristic such as hostility might moderate the effect of BP on LVM.
Finally, there can also be other costs associated with implementing one particular methodology over another. For example, while ABPM is considered the gold standard for BP measurement, ABPM also has lower acceptance rates by patients. 16 As with any study, researchers must weigh the benefits of collecting data using a particular methodology with the costs concerning compliance rates and data quality.
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